Señales en vivo de 28513K.KS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 02:30):

Stats
Volumen de hoy	709.00
Volumen promedio	3 118.00
Capitalización de mercado	1 079.10B
EPS	KRW0 ( 2023-09-30 )
Próxima fecha de ganancias	( KRW0 ) 2024-05-13
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW57.35 (0.21%)

Volumen Correlación

Largo: 0.23 (neutral)

Corto: -0.42 (neutral)

Signal:(56.033) Neutral

SK Chemicals Co.,Ltd Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SK Chemicals Co.,Ltd Correlación - Moneda/Commodity

-0.27
( neutral )

-0.25
( neutral )

-0.29
( neutral )

-0.11
( neutral )

0.27
( neutral )

SK Chemicals Co.,Ltd Finanzas

Annual	2023
Ingresos:	KRW1 748.78B
Beneficio Bruto:	KRW460.54B (26.33 %)
EPS:	KRW2 077.30

FY	2023
Ingresos:	KRW1 748.78B
Beneficio Bruto:	KRW460.54B (26.33 %)
EPS:	KRW2 077.30

FY	2022
Ingresos:	KRW1 829.19B
Beneficio Bruto:	KRW615.09B (33.63 %)
EPS:	KRW9 915.20

FY	2021
Ingresos:	KRW2 089.63B
Beneficio Bruto:	KRW881.38B (42.18 %)
EPS:	KRW5 351.19

Financial Reports:

No articles found.

SK Chemicals Co.,Ltd

SK Chemicals Co., Ltd. provides chemicals and life sciences products and solutions in South Korea and internationally. The company develops copolysters, coating and adhesive materials, engineering plastics, prepergs, bio materials, and 3D printing materials, as well as specialty chemicals, pharmaceutical products, and vaccines. It has a collaborate agreement with Standigm, Inc. to develop an AI-driven drug candidate for non-alcoholic steatohepatitis. The company was founded in 1969 and is headquartered in Seongnam, South Korea.